Expanding into Peripheral Vascular Treatments
Stryker (NYSE: SYK) has announced a definitive agreement to acquire Inari Medical, Inc. (NASDAQ: NARI) for $80 per share in cash, totaling approximately $4.9 billion. This acquisition marks Stryker’s entry into the high-growth peripheral vascular segment, addressing conditions like venous thromboembolism (VTE).
Key Highlights
- Innovative Portfolio: Inari’s mechanical thrombectomy solutions for deep vein thrombosis and pulmonary embolism complement Stryker’s Neurovascular division.
- VTE Impact: VTE affects up to 900,000 individuals annually in the U.S. alone. Inari’s solutions target this unmet need by enabling clot removal without thrombolytic drugs.
- Strategic Fit: Stryker aims to elevate the standard of care for VTE patients while expanding its endovascular capabilities.
Kevin Lobo, Stryker CEO, stated:
“This acquisition elevates our portfolio, providing life-saving solutions for patients with peripheral vascular diseases and accelerating our impact in endovascular procedures.”
Drew Hykes, Inari CEO, added:
“With Stryker’s global infrastructure, we are better positioned to expand innovative solutions and improve patient outcomes.”
Deal Overview
- Tender Offer: Stryker will acquire all outstanding shares at $80 per share.
- Regulatory Approvals: The deal requires clearance under the Hart-Scott-Rodino Antitrust Improvements Act.
- Expected Close: The transaction is anticipated to conclude by Q1 2025.
About the Companies
- Stryker: A global leader in medical technologies, impacting over 150 million patients annually across MedSurg, Neurotechnology, Orthopaedics, and Spine.
- Inari Medical: Innovator in thrombectomy solutions, addressing unmet needs in VTE care with purpose-built tools and education initiatives.
This acquisition solidifies Stryker’s commitment to advancing vascular health and enhancing patient outcomes worldwide.
Follow MEDWIRE.AI for updates on transformative deals and innovations shaping the future of healthcare.
